Wedbush Forecasts Chimerix's FY2025 Earnings (NASDAQ:CMRX)

Chimerix, Inc. (NASDAQ:CMRX - Free Report) - Equities research analysts at Wedbush increased their FY2025 earnings estimates for Chimerix in a note issued to investors on Tuesday, February 18th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings per share of ($0.03) for the year, up from their previous forecast of ($1.09). Wedbush has a "Outperform" rating and a $7.00 price objective on the stock. The consensus estimate for Chimerix's current full-year earnings is ($0.99) per share. Wedbush also issued estimates for Chimerix's Q4 2025 earnings at $0.74 EPS, FY2026 earnings at ($0.89) EPS and FY2027 earnings at $0.02 EPS.

Separately, HC Wainwright reiterated a "buy" rating and issued a $11.00 price target on shares of Chimerix in a research report on Tuesday.

Chimerix Price Performance

Shares of Chimerix stock traded down $0.01 during trading hours on Thursday, reaching $5.16. The company's stock had a trading volume of 1,966,579 shares, compared to its average volume of 1,665,416. The firm has a 50 day moving average price of $3.77 and a 200-day moving average price of $1.95. The stock has a market cap of $464.45 million, a P/E ratio of -5.49 and a beta of 0.35. Chimerix has a one year low of $0.75 and a one year high of $5.53.

Hedge Funds Weigh In On Chimerix

Hedge funds have recently bought and sold shares of the business. Bender Robert & Associates bought a new stake in shares of Chimerix during the fourth quarter worth $37,000. Susquehanna Fundamental Investments LLC purchased a new position in Chimerix in the 4th quarter worth about $59,000. Jane Street Group LLC bought a new stake in Chimerix during the 4th quarter valued at about $62,000. Diadema Partners LP purchased a new stake in Chimerix in the 4th quarter valued at about $101,000. Finally, Squarepoint Ops LLC bought a new position in Chimerix in the 4th quarter worth about $130,000. Institutional investors own 45.42% of the company's stock.

Insider Buying and Selling at Chimerix

In related news, CEO Michael T. Andriole sold 7,370 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the sale, the chief executive officer now directly owns 609,603 shares of the company's stock, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 20,760 shares of company stock worth $91,175 over the last quarter. Insiders own 13.10% of the company's stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.